Edupharma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 1,490,153 | 2,859,456 | 6,575,508 | 11,933,847 | 12,926,386 | 9,012,382 | 6,433,540 | 8,552,805 |
| Profit before tax | 103,204 | 287,992 | 1,176,107 | 1,589,435 | 1,875,181 | 1,187,438 | 38,517 | 361,648 |
| Net profit | 87,427 | 241,515 | 997,181 | 1,343,479 | 1,589,871 | 1,005,392 | 9,865 | 293,911 |
| Equity | 626,058 | 698,117 | 1,480,798 | 2,360,747 | 2,881,099 | 2,624,459 | 1,634,324 | 1,778,235 |
| Liabilities | 70,819 | 252,182 | 290,298 | 2,875,296 | 2,350,337 | 1,018,304 | 580,678 | 371,924 |
| Non-current assets | 60,027 | 75,721 | 63,782 | 120,585 | 104,322 | 160,356 | 563,519 | 524,263 |
| Current assets | 636,850 | 870,319 | 1,702,575 | 5,110,137 | 5,121,835 | 3,472,411 | 1,641,547 | 1,615,392 |
| Total assets | 696,877 | 946,040 | 1,766,357 | 5,230,722 | 5,226,157 | 3,632,767 | 2,205,066 | 2,139,655 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 544,905 | 266,956 | - |
| Social insurance contributions | - | - | - | - | - | 69,663 | 76,935 | 84,368 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -24.0% | +91.9% | +130.0% | +81.5% | +8.3% | -30.3% | -28.6% | +32.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 12.5% | 25.5% | 56.5% | 25.7% | 30.4% | 27.7% | 0.4% | 13.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 14.0% | 34.6% | 67.3% | 56.9% | 55.2% | 38.3% | 0.6% | 16.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 5.9% | 8.4% | 15.2% | 11.3% | 12.3% | 11.2% | 0.2% | 3.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 6.9% | 10.1% | 17.9% | 13.3% | 14.5% | 13.2% | 0.6% | 4.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 0.4 | 0.2 | 1.2 | 0.8 | 0.4 | 0.4 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 244,958 | 418,459 | 939,358 | 1,556,582 | 1,615,798 | 1,126,548 | 677,215 | 877,211 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Edupharma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-05-17 | 2026-05-20 | 0.01 |
Edupharma - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Edupharma, UAB (code 302549335) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In 2025, the company generated €8.55M in revenue, up 32.9% year on year, and reported net profit of €293.9K, giving a profit margin of 3.4%. This marked a clear recovery from 2024, when revenue was €6.43M and net profit was only €9.9K, after a stronger 2023 result of €9.01M in revenue and €1.01M in net profit. Over the two-year period from 2023 to 2025, revenue was down 5.1%, while profitability improved materially from the weak 2024 base. At the end of 2025, total assets stood at €2.14M, equity at €1.78M, and liabilities at €371.9K. The equity ratio was 83.1% and debt-to-equity was 0.21, indicating a conservatively leveraged balance sheet. Asset turnover reached 4.00x, and revenue per employee was €950.3K, with profit per employee at €32.7K.